参考文献/References:
[1] Okosieme OE,Lazarus JH.Current trends in antithyroid drug treatment of Graves' disease[J].Expert Opin Pharmacother,2016,17(15):2005-2017.DOI:10.1080/14656566.2016.1232388.
[2] Abulayha A,Bredan A,El Enshasy H,et al.Rituximab: modes of action, remaining dispute and future perspective[J].Future Oncol,2014,10(15):2481-2492.DOI:10.2217/fon.14.146.
[3] Ueki I,Abiru N,Kobayashi M,et al.B cell-targeted therapy with anti-CD20 monoclonal antibody in a mouse model of Graves' hyperthyroidism[J].Clin Exp Immunol,2011,163(3):309-317.DOI:10.1111/j.1365-2249.2010.04301.x.
[4] Braley-Mullen H,Yu S.Early requirement for B cells for development of spontaneous autoimmune thyroiditis in NOD.H-2h4 mice[J].J Immunol,2000,165(12):7262-7269.
[5] Pichurin P,Aliesky H,Chen CR,et al.Thyrotrophin receptor-specific memory T cell responses require normal B cells in a murine model of Graves' disease[J].Clin Exp Immunol,2003,134(3):396-402.
[6] Rudnicki M.Rituximab for treatment of membranoproliferative glomerulonephritis and C3 glomerulopathies[J].Biomed Res Int,2017,2017:2180508.DOI:10.1155/2017/2180508.
[7] Lenz G,Dreyling M,Hoster E,et al.Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group(GLSG)[J].J Clin Oncol,2005,23(9):1984-1992. DOI:10.1200/JCO.2005.08.133.
[8] Vannucchi G,Campi I,Bonomi M,et al.Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions[J].Clin Exp Immunol,2010,161(3):436-443.DOI:10.1111/j.1365-2249.2010.04191.x.
[9] El Fassi D,Nielsen CH,Bonnema SJ,et al.B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study[J].J Clin Endocrinol Metab,2007,92(5):1769-1772.DOI:10.1210/jc.2006-2388.
[10] Heemstra KA,Toes RE,Sepers J,et al.Rituximab in relapsing Graves' disease, a phase Ⅱ study[J].Eur J Endocrinol,2008,159(5):609-615.DOI:10.1530/EJE-08-0084.
[11] El Fassi D,Banga JP,Gilbert JA,et al.Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies[J].Clin Immunol,2009,130(3):252-258.DOI: 10.1016/j.clim.2008.09.007.
[12] Salvi M,Vannucchi G,Campi I,et al.Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study[J].Eur J Endocrinol,2007,156(1):33-40. DOI:10.1530/eje.1.02325.
[13] Liu X,Guo H,Liu J,et al.Clinical efficacy of combined rituximab treatment in a woman with severe Graves' ophthalmopathy[J].Exp Ther Med,2016,12(2):1093-1096.DOI:10.3892/etm.2016.3367.
[14] Vallerskog T,Gunnarsson I,Widhe M,et al.Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE[J].Clin Immunol,2007,122(1):62-74.DOI:10.1016/j.clim.2006.08.016.
[15] Stasi R,Stipa E,Del Poeta G,et al.Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab[J].Rheumatology(Oxford),2006,45(11):1432-1436.DOI:10.1093/rheumatology/kel098.
[16] 冯凯旋,任丽君,夏振娜,等.抗CD20单克隆抗体研究进展[J].中外健康文摘,2013,10(25):123-124.
[17] 陈净,李剑.利妥昔单抗的罕见不良反应[J].药物不良反应杂志,2010,12(5):321-323.DOI:10.3969/j.issn.1008-5734.2010.05.005.
[18] El Fassi D,Nielsen CH,Junker P,et al.Systemic adverse events following rituximab therapy in patients with Graves' disease[J].J Endocrinol Invest,2011,34(7):e163-e167.DOI:10.3275/7411.
相似文献/References:
[1]贾媛媛,陈莉丽.Th17细胞与Graves病及桥本甲状腺炎[J].国际内分泌代谢杂志,2014,(05):344.[doi:10.3760/cma.j.issn.1673-4157.2014.05.016]
Jia Yuanyuan,Chen Lili.Relationship between Th17 cells and Graves' disease,Hashimoto's thyroiditis[J].International Journal of Endocrinology and Metabolism,2014,(02):344.[doi:10.3760/cma.j.issn.1673-4157.2014.05.016]
[2]房方,卫红艳,王坤玲,等.硒治疗自身免疫性甲状腺疾病的荟萃分析[J].国际内分泌代谢杂志,2016,36(04):247.[doi:10.3760/cma.j.issn.1673-4157.2016.04.09]
Fang Fang,Wei Hongyan,Wang Kunling,et al.A meta-analysis of selenium in the treatment of autoimmune thyroid diseases[J].International Journal of Endocrinology and Metabolism,2016,36(02):247.[doi:10.3760/cma.j.issn.1673-4157.2016.04.09]
[3]郑仁东,刘超.白细胞介素-6与甲状腺疾病[J].国际内分泌代谢杂志,2016,36(05):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
Zheng Rendong,Liu Chao.Interleukin-6 and thyroid disease[J].International Journal of Endocrinology and Metabolism,2016,36(02):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
[4]郑慧娟,魏璠,魏军平.自噬与自身免疫性甲状腺疾病[J].国际内分泌代谢杂志,2017,37(01):17.[doi:10.3760/cma.j.issn.1673-4157.2017.01.05]
Zheng Huijuan,Wei Fan,Wei Junping..Autophagy and autoimmune thyroid disease[J].International Journal of Endocrinology and Metabolism,2017,37(02):17.[doi:10.3760/cma.j.issn.1673-4157.2017.01.05]
[5]苏亚峰 相萍萍 陈国芳 刘超.碘治疗Graves病的研究进展[J].国际内分泌代谢杂志,2019,39(01):21.[doi:10.3760/cma.j.issn.1673-4157.2019.01.005]
Su Yafeng,Xiang Pingping,Chen Guofang,et al.Research progress of iodine in treating Graves' disease[J].International Journal of Endocrinology and Metabolism,2019,39(02):21.[doi:10.3760/cma.j.issn.1673-4157.2019.01.005]
[6]赫晓晴 单忠艳.肠道菌群与自身免疫性甲状腺疾病[J].国际内分泌代谢杂志,2020,40(03):179.[doi:10.3760/cma.j.issn.1673-4157.2020.03.008]
He Xiaoqing,Shan Zhongyan.Gut microbiota and autoimmune thyroid disease[J].International Journal of Endocrinology and Metabolism,2020,40(02):179.[doi:10.3760/cma.j.issn.1673-4157.2020.03.008]
[7]刘天琪,张秀英,纪立农.促甲状腺激素受体抗体的检测及应用进展[J].国际内分泌代谢杂志,2021,41(01):5.[doi:10.3760/cma.j.cn121383-20200608-06021]
Liu Tianqi,Zhang Xiuying,Ji Linong..Progression of assay and clinical practice of thyroid stimulating hormone receptor antibody[J].International Journal of Endocrinology and Metabolism,2021,41(02):5.[doi:10.3760/cma.j.cn121383-20200608-06021]
[8]龙丽 张秀英 纪立农.甲状腺相关眼病治疗新希望——IGF-Ⅰ受体拮抗剂[J].国际内分泌代谢杂志,2022,42(04):256.[doi:10.3760/cma.j.cn121383-20210420-04055]
Long Li,Zhang Xiuying,Ji Linong..New hope for the treatment of thyroid associated orbitopathy-IGF-Ⅰ receptor antagonist[J].International Journal of Endocrinology and Metabolism,2022,42(02):256.[doi:10.3760/cma.j.cn121383-20210420-04055]